Withdrawal of the marketing authorisation application for balugrastim

On 4 November 2014, Teva Pharma B.V. officially notified the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for balugrastim (Egranli), for reduction in the duration of neutropaenia and the occurrence of febrile neutropaenia in adult cancer patients. Read more here.